Alcohol and Drug Abuse Research Center
Center for Depression, Anxiety and Stress Research
McLean Imaging Center
Clinical Unit Based Research
Mailman Research Center
Shervert H. Frazier Research Institute
Clinical Trials
Inventions for License
Research News


MCL 1811.0: Agents for Treatment of Cognitive Disorders

Perry Renshaw, M.D., Ph.D., et al.

Background and Description

Changes in the physical and chemical properties of the cell membrane can lead to changes in membrane fluidity, which in turn can have significant effects on membrane-linked functions such as ion transport and signal transduction. Use of a particular class of compounds, known to have an effect on one component of cell membranes, is proposed for the treatment of particular cognitive disorders where membrane fluidity appears to be an important factor in causing decreased brain cell function.

Potential Commercial Uses

The invention comprises a method of treating disorders like memory loss, cognitive impairment, and dementia, as well as depression, bipolar disorder and schizoaffective disorder. The method involves treatment of patients with agents which affect membrane fluidity. The cholesterol-lowering drugs known as the statins are believed to be particularly useful in the methods of the invention.

Publication and Patent Status

McLean Hospital is the owner of pending U.S. patent applications claiming this invention.

Licenses Available

McLean Hospital is offering a worldwide exclusive license to this technology.

For more information, please contact:

David J. Glass, Ph.D.
Senior Associate Director, Technology Transfer
McLean Hospital Research Administration
115 Mill Street
Belmont, MA 02478-9106
(617) 855-3825 - tel
(617) 855-3745 - fax